Study: Donor stem cells boost survival of patients with high-risk AML

06/9/2009 | Forbes

U.S. researchers found that allogeneic stem cell transplantation, which uses donor stem cells, was more effective than autologous cell transplantation and chemotherapy in improving survival and reducing the risk of relapse in patients with poor and intermediate risk of survival from acute myeloid leukemia. The study suggests that allogeneic transplant could be used as a standard treatment for most patients in the intermediate-risk group, one of the researchers said.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA